Sample size determination in group-sequential clinical trials with two co-primary endpoints

Statistics in Medicine

Volumn 33, Issue 17, 2014, Pages 2897-2913

  Asakura, Koko ^a,b   Hamasaki, Toshimitsu ^a,b   Sugimoto, Tomoyuki ^c   Hayashi, Kenichi ^a   Evans, Scott R ^d   Sozu, Takashi ^e  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^e KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

Author keywords

Average sample number; Co primary endpoints; Conditional power; Cui Hung Wang statistics; Group sequential methods; Maximum sample size; Sample size recalculation; Type I error

Indexed keywords

ARTICLE; AVERAGING; CALCULATION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DATA ANALYSIS; DECISION MAKING; EFFECT SIZE; MATHEMATICAL COMPUTING; SAMPLE SIZE; SIMULATION; STATISTICAL SIGNIFICANCE; ALZHEIMER DISEASE; COGNITION; DAILY LIFE ACTIVITY; DRUG EFFECTS; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; PROCEDURES; STATISTICAL MODEL; TREATMENT OUTCOME;

FLURBIPROFEN; TARENFLURBIL;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COGNITION; FLURBIPROFEN; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84903817449     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6154     Document Type: Article

References (33)

1. Committee for Medicinal Products for Human Use (CHMP). Guideline on Medicinal Products for the Treatment Alzheimer's Disease and Other Dementias (CPMP/EWP/553/95 Rev.1). EMEA: London, 2008.
2. Offen W, Chuang-Stein C, Dmitrienko A, Littman G, Maca J, Meyerson L, Muirhead R, Stryszak P, Boddy A, Chen K, Copley-Merriman K, Dere W, Givens S, Hall D, Henry D, Jackson JD, Krishen A, Liu T, Ryder S, Sankoh AJ, Wang J, Yeh CH. Multiple co-primary endpoints: medical and statistical solutions. Drug Information Journal 2007; 41:31-46. DOI: 10.1177/009286150704100105.
3. Hung HMJ, Wang SJ. Some controversial multiple testing problems in regulatory applications. Journal of Biopharmaceutical Statistics 2009; 19:1-11. DOI: 10.1080/10543400802541693.
4. Dmitrienko A, Tamhane AC, Bretz F. Multiple Testing Problems in Pharmaceutical Statistics. Chapman & Hall: Boca Raton, FL., 2010.
5. Xiong C, Yu K, Gao F, Yan Y, Zhang Z. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial. Clinical Trials 2005; 2:387-393. DOI: 10.1191/1740774505cn112oa.
6. Sozu T, Kanou T, Hamada C, Yoshimura I. Power and sample size calculations in clinical trials with multiple primary variables. Japanese Journal of Biometrics 2006; 27:83-96. DOI: 10.5691/jjb.27.83.
7. Chuang-Stein C, Stryszak P, Dmitrienko A, Offen W. Challenge of multiple co-primary endpoints: a new approach. Statistics in Medicine 2007; 26:1181-1192. DOI: 10.1002/sim.2604.
8. Eaton ML, Muirhead RJ. On multiple endpoints testing problem. Journal of Statistical Planning & Inference 2007; 137:3416-3429. DOI: 10.1016/j.jspi.2007.03.021.
9. Senn S, Bretz F. Power and sample size when multiple endpoints are considered. Pharmaceutical Statistics 2007; 6:161-170. DOI: 10.1002/pst.301.
10. Kordzakhia G, Siddiqui O, Huque MF. Method of balanced adjustment in testing co-primary endpoints. Statistics in Medicine 2010; 29:2055-2066. DOI: 10.1002/sim.3950.
11. Sozu T, Sugimoto T, Hamasaki T. Sample size determination in clinical trials with multiple co-primary binary endpoints. Statistics in Medicine 2010; 29:2169-2179. DOI: 10.1002/sim.3972.
12. Sozu T, Sugimoto T, Hamasaki T. Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints. Journal of Biopharmaceutical Statistics 2011; 21:650-668. DOI: 10.1080/10543406.2011.551329.
13. Julious S, Mclntyre NE. Sample sizes for trials involving multiple correlated must-win comparisons. Pharmaceutical Statistics 2012; 11:177-185. DOI: 10.1002/pst.515.
14. Sugimoto T, Sozu T, Hamasaki T. A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints. Pharmaceutical Statistics 2012; 11:118-128. DOI: 10.1002/pst.505.
15. Hamasaki T, Sugimoto T, Evans SR, Sozu T. Sample size determination for clinical trials with co-primary outcomes: exponential event times. Pharmaceutical Statistics 2013; 12:28-34. DOI: 10.1002/pst.1545.
16. Sugimoto T, Sozu T, Hamasaki T, Evans SR. A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints. Biostatistics 2013; 14:409-421. DOI: 10.1093/biostatistics/kxs057.
17. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663. DOI: 10.1093/biomet/70.3.659.
18. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556. DOI: 10.2307/2530245.
19. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64:191-199. DOI: 10.1093/biomet/64.2.191.
20. Glimm E, Maurer W, Bretz F. Hierarchical testing of multiple endpoints in group-sequential trials. Statistics in Medicine 2010; 29:219-228. DOI: 10.1002/sim.3748.
21. Tamhane AC, Mehta CR, Liu L. Testing a primary and secondary endpoint in a group sequential design. Biometrics 2010; 66:1174-1184. DOI: 10.1111/j.1541-0420.2010.01402.x.
22. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH, for the Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. Journal of the American Medical Association 2009; 302:2557-2564. DOI: 10.1001/jama.2009.1866.
23. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B. The Alzheimer's disease assessment scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology 1997; 48:1511-1517. DOI: 10.1212/WNL.48.6.1511.
24. Cui L, Hung HMJ, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics 1999; 55:853-857. DOI: 10.1111/j.0006-341X.1999.00853.x.
25. Asakura K, Hayashi K, Sugimoto T, Sozu T, Hamasaki T. Sample size evaluation in group sequential designs for clinical trials with two continuous endpoints as co-primary contrasts. Joint Statistical Meetings 2013, Montreal, Quebec, Canada, August 3-8, 2013.
26. Hamasaki T, Asakura K, Sugimoto T, Evans SR. Sample size modification in group-sequential clinical trials with two co-primary endpoints. Proceedings of Joint Meeting of the IASC Satellite Conference and 8th Conference of the Asian Regional Section of the IASC, Seoul, Korea, August 21-14, 2013; 311-317.
27. Moyé LA. Multiple Analyses in Clinical Trials. Springer: New York, NY, 2003.
28. Moyé LA, Baraniuk S. Dependence, hyper-dependence and hypothesis testing in clinical trials. Contemporary Clinical Trials 2013; 28:68-78. DOI: 10.1016/j.cct.2006.05.010.
29. Jennison C, Turnbull BW. Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety. Biometrics 1993; 49:741-752.
30. Tang DI, Geller NL. Closed testing procedures for group sequential clinical trials with multiple endpoints. Biometrics 1999; 55:1188-1192. DOI: 10.1111/j.0006-341X.1999.01188.x.
31. Tamhane AC, Wu Y, Mehta C. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints. Statistics in Medicine 2012; 31:2027-2040. DOI: 10.1002/sim.5372.
32. Tamhane AC, Wu Y, Mehta C. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation. Statistics in Medicine 2012; 31:2041-2054. DOI: 10.1002/sim.5377.
33. Genz A, Bretz F. Computation of Multivariate Normal and t Probabilities. Springer Verlag: Berlin, 2009.